Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

Sebastian Stintzing, Volker Heinemann, Alexander Kiani et al.|European Journal of Cancer|2017

Cited by 139